All Oncology News

Hans Wildier, MD, provides an overview of the TH3RESA study and discusses the trial’s significance in the field of HER2-positive breast cancer.

Ezra Cohen, MD, discusses results of a biomarker analysis and the next steps in understanding biomarkers for afatinib in patients with head and neck cancer.

An expert panel has developed clinical practice guidelines for the management of head and neck cancer survivors.

Martee L. Hensley, MD, discusses what lies ahead for the treatment paradigm of uterine leiomyosarcoma

The combination of liposomal irinotecan (irinotecan liposome injection; Onivyde), fluorouracil, and leucovorin has been added to the 2016 NCCN Clinical Practice Guidelines in Oncology as a second-line treatment for patients with gemcitabine-refractory metastatic pancreatic cancer.

John Byrd, MD, explains why he believes the ibrutinib approval is practice changing, and how he thinks the agent should be utilized next.

George Demetri, MD, discusses the impact of the eribulin’s FDA approval, what oncologists can learn from studying liposarcoma, and the challenges that come with treating a rare disease.

Joyce O’Shaughnessy, MD, discusses how four agents—palbociclib (Ibrance), pembrolizumab (Keytruda), abemaciclib (LY2835219), and buparlisib (BKM120)—are worth examining in estrogen receptor-positive breast cancer.

Leonard Gomella, MD, discusses the optimal patient population to receive radium-223 for prostate cancer and how oncologists should best use it.

Mario Sznol, MD, discusses the current state of immunotherapy in renal cell carcinoma, emerging agents and combinations in the field, and the challenges that arise with finding biomarkers.

Targeting androgen receptor signaling with recently approved agents has improved outcomes for men with metastatic castration-resistant prostate cancer but significant questions linger about how to tackle resistance to the therapies.

E. David Crawford, MD, discusses the history of radium-223 dichloride (Xofigo) and how it could be used in the future.

Elizabeth Mittendorf, MD, PhD, discusses checkpoint inhibition studies in triple-negative breast cancer, potential ways to make other subtypes more immunogenic to improve response, the role of PD-1, and what’s next in the field of immunotherapy in breast cancer.

The accumulation of evidence supporting a regimen of anthracycline and taxanes for breast cancer has led some oncologists to argue for the establishment of a standard treatment plan that deemphasizes or eliminates alternative options.

The Wistar Institute is pleased to welcome Cavan Redmond to its Board of Trustees.

Stacy Loeb, MD, discusses how screening tests for prostate cancer work, what their benefits are, and what urological specialists need to know in order to best utilize them.

Scott J. Antonia, MD, discusses how the combination of the PD-L1 inhibitor durvalumab and the CTLA-4 inhibitor tremelimumab, showed antitumor activity in patients with locally advanced or metastatic non–small cell lung cancer, irrespective of PD-L1 status.

Constance D. Lehman, MD, PhD, explains how tomosynthesis, otherwise known as 3D mammography, is already recognized as the new standard of care in terms of breast cancer screening.

Mitchell Smith, MD, discusses advancements in the field of non-Hodgkin lymphoma.

The FDA has granted a priority review to atezolizumab as a treatment for patients with locally advanced or metastatic urothelial carcinoma who progressed during or after platinum-based chemotherapy in the metastatic setting, or whose disease worsened within 12 months of receiving platinum-based chemotherapy before or after surgery.

A supplemental new drug application has been submitted to the FDA for ofatumumab in combination with fludarabine and cyclophosphamide for the treatment of patients with relapsed chronic lymphocytic leukemia.

The FDA has approved Captisol-enabled melphalan (Evomela) as a high-dose conditioning treatment for use in patients with multiple myeloma prior to autologous stem cell transplantation, as well as for the palliative treatment of patients with myeloma for whom oral therapy is not appropriate.

Frontline treatment with CPX-351 (Vyxeos) significantly reduced the risk of death by 31% compared with cytarabine and daunorubicin (7+3) for older patients with high-risk, secondary acute myeloid leukemia.

Timothy W. Strawderman, PhD, has been named the new Executive Director of the Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center, an NCI-designated cancer center.

Matthew Galsky, MD, explains the challenges of utilizing molecular subtyping and PD-L1 as biomarkers, the impact a potential approval of atezolizumab could have in metastatic bladder cancer, possible combinations that could increase ORR, and next steps in understanding the IMvigor study.

Six clinical trials exploring idelalisib in combination other therapies for patients with hematologic malignancies have been halted due to reports of an increased rate of adverse events, including death.

Treatment with abiraterone acetate plus prednisone demonstrated an 11.8-month improvement in overall survival compared with prednisone and placebo for men with less advanced, chemotherapy-naïve metastatic castration-resistant prostate cancer.

Men with low-risk prostate cancer who chose active surveillance (AS) reported a higher quality of life than men who chose direct active treatment such as surgery or radiation.

Finding is relevant to certain cancers of the blood.

The collaboration will bring together exceptional researchers from the United States and Israel.